Reuters

Novo Nordisk says semaglutide cut obesity rates in young children in trial

The Wall Street Journal

Novo Nordisk Says Wegovy Shot Helped Children Lose Weight in Trial

Novo Nordisk

Novo Nordisk STEP Young phase 3 data: 40.4% of children living with obesity achieved a BMI below the obesity threshold with semaglutide and lifestyle modification

The Pharmacist

Weight-loss injections cut obesity rates in children, study finds

University of Cambridge

Nutrition must stay central to obesity management medication for children and adolescents

Spectator (UK)

Should we give weight loss jabs to children?

American Academy of Pediatrics

Glp 1 Prescription Rates In Young Children Are

Metaculus

Oral Semaglutide Approval by 2027

The Danish pharmaceutical company Novo Nordisk announced on Monday that 40.4% of children aged 6 to under 12 treated with semaglutide in its late-stage STEP Young trial were no longer obese after 68 weeks, assuming full adherence to treatment.

The Danish pharmaceutical company Novo Nordisk announced on Monday that 40.4% of children aged 6 to under 12 treated with semaglutide in its late-stage STEP Young trial were no longer obese after 68 weeks, assuming full adherence to treatment.

The company said the trial met its primary endpoint, with those taking subcutaneous semaglutide once weekly showing greater BMI reduction at week 68 than those on the placebo, none of whom dropped below the obesity threshold.

The company said the trial met its primary endpoint, with those taking subcutaneous semaglutide once weekly showing greater BMI reduction at week 68 than those on the placebo, none of whom dropped below the obesity threshold.

In total, the randomized, double-blind, placebo-controlled trial enrolled 165 children with obesity, more than 85% of whom were class II or III, who received a maximum dose of either 1.7 mg or 2.4 mg of semaglutide depending on their weight at the start of the study.

In total, the randomized, double-blind, placebo-controlled trial enrolled 165 children with obesity, more than 85% of whom were class II or III, who received a maximum dose of either 1.7 mg or 2.4 mg of semaglutide depending on their weight at the start of the study.

Along with semaglutide or placebo, all participants also adopted multiple lifestyle changes during the trial, including a reduced-calorie diet and increased physical activity.

Along with semaglutide or placebo, all participants also adopted multiple lifestyle changes during the trial, including a reduced-calorie diet and increased physical activity.

According to Novo Nordisk, the study's overall safety and tolerability results matched earlier adult and adolescent trials, with no new safety concerns and none identified for growth or pubertal development. Detailed trial data are due to be presented in Washington in November.

According to Novo Nordisk, the study's overall safety and tolerability results matched earlier adult and adolescent trials, with no new safety concerns and none identified for growth or pubertal development. Detailed trial data are due to be presented in Washington in November.

It follows a separate study published Friday that found that prescriptions for GLP-1 weight-loss drugs among U.S. children under 12 have risen more than 300-fold since 2019, though the drugs are not approved for that age group.

It follows a separate study published Friday that found that prescriptions for GLP-1 weight-loss drugs among U.S. children under 12 have risen more than 300-fold since 2019, though the drugs are not approved for that age group.

Reuters #

The Wall Street Journal #

Novo Nordisk #

The Pharmacist #

University of Cambridge #

Spectator (UK) #

American Academy of Pediatrics #

Metaculus #

Novo Nordisk announced Monday that in its late-stage STEP Young trial, 40.4% of children aged 6 to under 12 treated with semaglutide were no longer classified as having obesity after 68 weeks, assuming full adherence to treatment.

Novo Nordisk announced Monday that in its late-stage STEP Young trial, 40.4% of children aged 6 to under 12 treated with semaglutide were no longer classified as having obesity after 68 weeks, assuming full adherence to treatment.

The company said the trial met its primary endpoint, showing superior body mass index reduction at week 68 among children on once-weekly subcutaneous semaglutide compared with those given a placebo, none of whom dropped below the obesity threshold.

The company said the trial met its primary endpoint, showing superior body mass index reduction at week 68 among children on once-weekly subcutaneous semaglutide compared with those given a placebo, none of whom dropped below the obesity threshold.

All participants received lifestyle modification during the trial, including a reduced-calorie diet and increased physical activity. Semaglutide is the active ingredient in Novo Nordisk's weight-loss drug Wegovy.

All participants received lifestyle modification during the trial, including a reduced-calorie diet and increased physical activity. Semaglutide is the active ingredient in Novo Nordisk's weight-loss drug Wegovy.

The randomized, double-blind, placebo-controlled trial enrolled 165 children with obesity, who received a maximum dose of either 1.7 mg or 2.4 mg of semaglutide based on their weight at the start of the study.

The randomized, double-blind, placebo-controlled trial enrolled 165 children with obesity, who received a maximum dose of either 1.7 mg or 2.4 mg of semaglutide based on their weight at the start of the study.

Novo Nordisk said overall safety and tolerability matched earlier adult and adolescent trials, with no new safety concerns and none identified for growth or pubertal development. More than 85% of participants had class II or III severe obesity at baseline.

Novo Nordisk said overall safety and tolerability matched earlier adult and adolescent trials, with no new safety concerns and none identified for growth or pubertal development. More than 85% of participants had class II or III severe obesity at baseline.

A study published Friday found that prescriptions for GLP-1 weight-loss drugs among U.S. children under 12 have risen more than 300-fold since 2019, though the drugs are not approved for that age group. Detailed trial data is due in November in Washington.

A study published Friday found that prescriptions for GLP-1 weight-loss drugs among U.S. children under 12 have risen more than 300-fold since 2019, though the drugs are not approved for that age group. Detailed trial data is due in November in Washington.

Two out of five kids on semaglutide dropped below the obesity threshold in 68 weeks, while not a single child on placebo did. Most of these children started with severe class II or III obesity, and diet and exercise advice alone was never going to fix that. Safety held up with no red flags for growth or puberty, so withholding an effective medicine from kids facing early heart disease and shortened lives makes no sense.

Two out of five kids on semaglutide dropped below the obesity threshold in 68 weeks, while not a single child on placebo did. Most of these children started with severe class II or III obesity, and diet and exercise advice alone was never going to fix that. Safety held up with no red flags for growth or puberty, so withholding an effective medicine from kids facing early heart disease and shortened lives makes no sense.

Handing appetite-suppressing drugs to grade schoolers because society lacks the spine to regulate junk food is a moral failure, not a medical breakthrough. Children are still growing physically, cognitively and emotionally, and rapid weight loss during those years carries real risks that long-term data has not answered. Without dietitians, growth and micronutrient monitoring and psychological support, prescribing is racing ahead of the safeguards.

Handing appetite-suppressing drugs to grade schoolers because society lacks the spine to regulate junk food is a moral failure, not a medical breakthrough. Children are still growing physically, cognitively and emotionally, and rapid weight loss during those years carries real risks that long-term data has not answered. Without dietitians, growth and micronutrient monitoring and psychological support, prescribing is racing ahead of the safeguards.

Health

Medicine & healthcare

Denmark

This trial shows promising results for semaglutide's effectiveness in children, with just over 40% dropping below the obesity threshold in 68 weeks. Most of these children had severe cases of obesity, and exercise and diet alone were never going to be enough. Since no safety red flags were raised, the medicine is viable for improved health outcomes in minors.

This trial shows promising results for semaglutide's effectiveness in children, with just over 40% dropping below the obesity threshold in 68 weeks. Most of these children had severe cases of obesity, and exercise and diet alone were never going to be enough. Since no safety red flags were raised, the medicine is viable for improved health outcomes in minors.

Handing appetite-suppressing drugs to children because society lacks the spine to regulate junk food is a moral failure, not a medical breakthrough. During their early years, children are still growing physically, cognitively and emotionally, and rapid weight loss carries real risks that long-term data has not answered. Jumping to prescribing these drugs could be disastrous.

Handing appetite-suppressing drugs to children because society lacks the spine to regulate junk food is a moral failure, not a medical breakthrough. During their early years, children are still growing physically, cognitively and emotionally, and rapid weight loss carries real risks that long-term data has not answered. Jumping to prescribing these drugs could be disastrous.

There is an 82% chance that an oral semaglutide will be approved for the treatment of obesity by the FDA or EMA by 2027, according to the Metaculus prediction community.

There is an 82% chance that an oral semaglutide will be approved for the treatment of obesity by the FDA or EMA by 2027, according to the Metaculus prediction community.

Novo Nordisk: Semaglutide Cuts Obesity in 40% of Kids Under 12

Novo Nordisk: saysSemaglutide semaglutideCuts cutObesity obesityin rates40% inof youngKids childrenUnder in trial12

The Spin

Metaculus Prediction

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters

Novo Nordisk: Semaglutide Cuts Obesity in 40% of Kids Under 12

Novo Nordisk: saysSemaglutide semaglutideCuts cutObesity obesityin rates40% inof youngKids childrenUnder in trial12

The Spin

Metaculus Prediction

Sign Up for Our Free NewslettersSign Up for Our Free Newsletters

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters